Dr Tal Zaks on the JAK2 Inhibitor SAR302503 in Myelofibrosis

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=aIcnkbVFUs4

Tal Zaks, MD, PhD, vice president and head of development at Sanofi Oncology, details a phase II randomized study of the JAK2 inhibitor SAR302503 in patients with intermediate-2 or high-risk primary myelofibrosis (MF), post-polycythemia vera MF, or post-essential thrombocythemia MF. • For more hematology and oncology resources: http://www.onclive.com/specialty/hema...

#############################

New on site